The Catalan pharmaceutical company Grifols reported a net profit of 227 million euros in the first half of 2026, a 28.7% increase compared to the previous year, despite a 3% drop in revenue, down to 3.5 billion.
Grifols, the pharmaceutical company based in Sant Cugat del Vallès, has presented its results for the first half of 2026 with a 28.7% increase in net profit, reaching 227 million euros. This growth contrasts with a slight 3% reduction in revenue, which stood at 3.5 billion euros, compared to 3.6 billion in the same period last year.
However, the company highlights that, at constant exchange rates, revenue grew by 2.6%. The improvement in profitability is the result of the operational efficiency strategy that the company has been implementing for months, as explained by its CEO, Nacho Abia.
The gross operating profit (EBITDA) also improved by 2%, reaching 854 million euros, reinforcing the financial consolidation path that the Catalan multinational is pursuing. Grifols has managed to increase its net earnings by nearly a third despite an adverse currency environment, which has weighed on revenue in absolute terms.
In a statement, Abia noted that the results reflect “the continued strength of our business and the disciplined execution of our strategy.” The executive added that the company remains “focused on driving sustainable growth, improving operational efficiency, and strengthening our financial position.”
Among the priorities for the next phase, Abia mentioned progress in Egypt, the evolution of the operational model, and advancements in the innovation portfolio. These projects are key to the future of the pharmaceutical company, which is headquartered in Sant Cugat del Vallès and is one of the most relevant companies in Vallès Occidental.
For readers in the province of Barcelona, these results are a good indicator of the economic health of one of the region's flagship companies. Grifols employs thousands of people in its production and research centres spread across Catalonia, and its evolution directly impacts the local business fabric.
The pharmaceutical company has managed to navigate currency volatility and inflationary pressure with a management focused on efficiency. The slight revenue reduction is mainly explained by the negative exchange rate effect, as Grifols derives a significant portion of its sales from international markets.
Looking ahead to the second half, the company is confident in maintaining the positive trend. Abia emphasized that it continues to “invest in long-term opportunities that will drive sustainable value creation for all our stakeholders.”
The results are known in the context of consolidation in the pharmaceutical sector, where Grifols competes with large multinationals. The Catalan company has managed to differentiate itself through its specialization in plasma-derived products and diagnostics, a niche that has allowed it to maintain attractive margins.
With these figures, Grifols reaffirms its position as one of the economic engines of the Vallès Occidental region and all of Catalonia. The company plans to present its full results to the National Securities Market Commission in the coming days.
You may also like
